Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Uplizna (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Uplizna (inebilizumab) significantly reduced the annualized relapse rate (ARR) compared to standard treatments, with a mean difference of -0.31 (-0.46 to -0.16), and exhibited a lower risk of relapse (HR 0.13, 95% CI 0.07 to 0.24).
• In terms of relapse rate, Uplizna was superior to satralizumab (lnOR -24.86, 95% CrI -73.75 to -1.93) but ranked below tocilizumab.
• Uplizna led to a reduction in Expanded Disability Status Scale (EDSS) scores, with a mean change of -0.51 (95% CI -0.92 to -0.11, P=0.01).
• Uplizna (inebilizumab) demonstrated a reduction in serious adverse events (RR 0.59, 95% CI 0.37 to 0.96, P=0.03), with no significant differences in total adverse events or mortality compared to placebo.
• No specific safety concerns or adverse effects were identified for particular subgroups, including those based on AQP4-IgG serostatus, for inebilizumab.
• The majority of patients (84.7%) were AQP4-IgG seropositive, with Eculizumab potentially more effective in reducing relapse risk for this subgroup; no specific safety concerns were noted for any particular subgroups with inebilizumab.